| Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor Z Culig, A Hobisch, MV Cronauer, C Radmayr, J Trapman, A Hittmair, ... Cancer research 54 (20), 5474-5478, 1994 | 1323 | 1994 |
| Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Z Culig, A Hobisch, MV Cronauer, AC Cato, A Hittmair, C Radmayr, ... Molecular endocrinology 7 (12), 1541-1550, 1993 | 613 | 1993 |
| Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor A Hobisch, IE Eder, T Putz, W Horninger, G Bartsch, H Klocker, Z Culig Cancer research 58 (20), 4640-4645, 1998 | 563 | 1998 |
| Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system Z Culig, J Hoffmann, M Erdel, IE Eder, A Hobisch, A Hittmair, G Bartsch, ... British journal of cancer 81 (2), 242-251, 1999 | 491 | 1999 |
| Nanoparticle-based bio-barcode assay redefines “undetectable” PSA and biochemical recurrence after radical prostatectomy CS Thaxton, R Elghanian, AD Thomas, SI Stoeva, JS Lee, ND Smith, ... Proceedings of the National Academy of Sciences 106 (44), 18437-18442, 2009 | 457 | 2009 |
| Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria G Bartsch, W Horninger, H Klocker, A Reissigl, W Oberaigner, ... Urology 58 (3), 417-424, 2001 | 431 | 2001 |
| Regulation of prostatic growth and function by peptide growth factors Z Culig, A Hobisch, MV Cronauer, C Radmayr, A Hittmair, J Zhang, ... The Prostate 28 (6), 392-405, 1996 | 404 | 1996 |
| Distant metastases from prostatic carcinoma express androgen receptor protein A Hobisch, Z Culig, C Radmayr, G Bartsch, H Klocker, A Hittmair Cancer research 55 (14), 3068-3072, 1995 | 382 | 1995 |
| Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells L HOLTL, C RIESER, C PAPESH, R RAMONER, M HEROLD, ... The Journal of urology 161 (3), 777-782, 1999 | 349 | 1999 |
| Prostaglandin E2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production C Rieser, G Böck, H Klocker, G Bartsch, M Thurnher The Journal of experimental medicine 186 (9), 1603-1608, 1997 | 347 | 1997 |
| Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection FH Jansen, RHN van Schaik, J Kurstjens, W Horninger, H Klocker, ... European urology 57 (6), 921-927, 2010 | 336 | 2010 |
| Rapid signalling by androgen receptor in prostate cancer cells H Peterziel, S Mink, A Schonert, M Becker, H Klocker, ACB Cato Oncogene 18 (46), 6322-6329, 1999 | 332 | 1999 |
| Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients H Fiegl, S Millinger, E Mueller-Holzner, C Marth, C Ensinger, A Berger, ... Cancer research 65 (4), 1141-1145, 2005 | 299 | 2005 |
| Dihydrotestosterone and the concept of 5α–reductase inhibition in human benign prostatic hyperplasia G Bartsch, RS Rittmaster, H Klocker European urology 37 (4), 367-380, 2000 | 293 | 2000 |
| Androgen receptors in prostate cancer. Z Culig, H Klocker, G Bartsch, A Hobisch Endocrine-related cancer 9 (3), 155-170, 2002 | 281 | 2002 |
| Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 M Puhr, J Hoefer, G Schäfer, HHH Erb, SJ Oh, H Klocker, I Heidegger, ... The American journal of pathology 181 (6), 2188-2201, 2012 | 269 | 2012 |
| Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml WJ Catalona, G Bartsch, HG Rittenhouse, CL Evans, HJ Linton, ... The Journal of urology 170 (6), 2181-2185, 2003 | 251 | 2003 |
| Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue A Hobisch, H Rogatsch, A Hittmair, D Fuchs, G Bartsch Jr, H Klocker, ... The Journal of pathology 191 (3), 239-244, 2000 | 223 | 2000 |
| Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen WJ Catalona, G Bartsch, HG Rittenhouse, CL Evans, HJ Linton, ... The Journal of urology 171 (6 Part 1), 2239-2244, 2004 | 218 | 2004 |
| Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity M Kerick, M Isau, B Timmermann, H Sültmann, R Herwig, S Krobitsch, ... BMC medical genomics 4, 1-13, 2011 | 215 | 2011 |
